Neratinib Approved for HER2+ Breast Cancer [News in Brief]

The FDA approved the tyrosine kinase inhibitor neratinib for extended adjuvant treatment of early-stage HER2-positive breast cancer. The decision adds another treatment option to help prevent recurrence, but its relatively small potential benefit must be weighed against the risk of serious side effects.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research